Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Business Wire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Q3 net revenue $193.4 million, up 16% year-over-year
- ➤2026 revenue guidance raised to $736 million-$743 million
- ➤2026 adjusted EBITDA guidance raised to $24 million-$34 million
- ➤Japan approved Optune Pax for locally advanced pancreatic cancer
- ➤Global active patients reached 5,260, up 19% year-over-year
Expert Statements
Frank Leonard, CEO of Novocure
“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies”
Frank Leonard, CEO of Novocure
“We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January.”
Frank Leonard, CEO of Novocure
“Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide
Get started
Create a free account to read the full story.